Last reviewed · How we verify
LDP-02
At a glance
| Generic name | LDP-02 |
|---|---|
| Also known as | MLN0002, MLN02 |
| Sponsor | Millennium Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (PHASE1)
- Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma (PHASE1, PHASE2)
- Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning (PHASE2)
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (PHASE3)
- Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease (PHASE3)
- Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab (PHASE1)
- Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease (PHASE2)
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LDP-02 CI brief — competitive landscape report
- LDP-02 updates RSS · CI watch RSS
- Millennium Pharmaceuticals, Inc. portfolio CI